Yeah it was a joke. Reporting that 2/3 improved is pointless and I would have preferred they omitted that comment. They could have commented on any observed changes to perfusion noted on MR but they didn't. This is basically a P1 trial so a long way still to go and I expect at some point the plan is to switch to the more variable afamelanotide dosing delivery in Prenumbra.
Having said that any update is pleasing
Ann: Afamelanotide well tolerated by first stroke patients, page-5
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |